Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Radiopharmaceuticals are increasingly playing a leading role in diagnosing, monitoring, and treating disease. In comparison with conventional pharmaceuticals, the development of radiopharmaceuticals does follow the principles of medicinal chemistry in the context of imaging-altered physiological processes. The design of a novel radiopharmaceutical has several steps similar to conventional drug discovery and some particularity. In the present work, we revisited the insights of medicinal chemistry in the current radiopharmaceutical development giving examples in oncology, neurology, and cardiology. In this regard, we overviewed the literature on radiopharmaceutical development to study overexpressed targets such as prostate-specific membrane antigen and fibroblast activation protein in cancer; β-amyloid plaques and tau protein in brain disorders; and angiotensin II type 1 receptor in cardiac disease. The work addresses concepts in the field of radiopharmacy with a special focus on the potential use of radiopharmaceuticals for nuclear imaging and theranostics. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Martha Sahylí Ortega Pijeira, Paulo Sérgio Gonçalves Nunes, Samila Leon Chaviano, Aida M Abreu Diaz, Jean N DaSilva, Eduardo Ricci-Junior, Luciana Magalhães Rebelo Alencar, Xiaoyuan Chen, Ralph Santos-Oliveira. Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future. Current medicinal chemistry. 2024;31(34):5481-5534

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 37594105

View Full Text